32 completed, 15 terminated, 6 unknown, 1 withdrawn. 54 Phase 2, 11 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 54 | Completed 32, Terminated 15, Unknown 6, Withdrawn 1 |
| Phase 1 | 11 | Completed 7, Terminated 3, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
Follow gene expression analysis: new trials by email Literature Review of gene expression analysis trials Research Report on gene expression analysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation bortezomib, rituximab, laboratory biomarker analysis - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 23 | 2011-10-03 | 2023-07-27 |
| Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma pomalidomide, bortezomib, dexamethasone - Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 50 | 2011-09-01 | 2020-04-17 |
| Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma prednisone, cyclophosphamide, etoposide - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | University of Nebraska | 34 | 2011-07-06 | 2023-09-22 |
| S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma bortezomib, cisplatin, cyclophosphamide - Multiple Myeloma, Plasma Cell Myeloma | Phase 2 | Withdrawn | SWOG Cancer Research Network | 2011-07-01 | 2015-03-06 | |
| Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction - Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 18 | 2011-01-01 | 2018-09-18 |
| Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck erlotinib hydrochloride, intensity-modulated radiation therapy, pharmacogenomic studies - Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx | Phase 2 | Terminated | Case Comprehensive Cancer Center | 2 | 2011-01-01 | 2020-05-12 |
| Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome flow cytometry, DNA methylation analysis, cytogenetic analysis - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Case Comprehensive Cancer Center | 25 | 2010-07-01 | 2019-03-04 |
| Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma azacitidine, lenalidomide, dexamethasone - Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Case Comprehensive Cancer Center | 45 | 2010-06-01 | 2020-11-16 |
| Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma defined green tea catechin extract, gene expression analysis, protein analysis - Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition | Phase 2 | Terminated | Barbara Ann Karmanos Cancer Institute | 8 | 2009-11-01 | 2015-03-27 |
| Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer bevacizumab, cetuximab, fluorouracil - Colorectal Cancer | Phase 2 / Phase 3 | Completed | Medical Research Council | 3240 | 2009-07-01 | 2013-12-19 |
| GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma rituximab, sargramostim, cyclophosphamide - Lymphoma | Phase 2 | Unknown | French Innovative Leukemia Organisation | 30 | 2009-03-01 | 2013-08-02 |
| GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma rituximab, sargramostim, gene expression analysis - Lymphoma | Phase 2 | Unknown | French Innovative Leukemia Organisation | 60 | 2009-03-01 | 2013-08-02 |
| Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment rituximab, bortezomib, pegylated liposomal doxorubicin hydrochloride - Lymphoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 9 | 2009-01-01 | 2014-07-21 |
| Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer ridaforolimus, gene expression analysis, immunohistochemistry staining method - Endometrial Cancer | Phase 2 | Completed | NCIC Clinical Trials Group | 35 | 2008-11-13 | 2023-08-04 |
| Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy imatinib mesylate, gene expression analysis, mutation analysis - Leukemia | Phase 2 | Completed | Case Comprehensive Cancer Center | 32 | 2008-10-01 | 2020-03-17 |
| PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction - Kaposi's Sarcoma | Phase 1 / Phase 2 | Terminated | AIDS Malignancy Consortium | 17 | 2008-09-01 | 2018-06-06 |
| CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 pegfilgrastim, rituximab, cyclophosphamide - Leukemia | Phase 2 | Completed | Cancer Trials Ireland | 52 | 2008-08-18 | 2025-07-08 |
| Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma gene expression analysis, polymerase chain reaction, western blotting - Sarcoma | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2008-07-01 | 2014-07-11 |
| Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen tamoxifen citrate, gene expression analysis, pharmacogenomic studies - Breast Cancer, Menopausal Symptoms | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 501 | 2008-06-18 | 2017-08-01 |
| Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Panitumumab, Irinotecan hydrochloride, Chromogenic in situ hybridization - Colorectal Cancer | Phase 2 | Completed | GERCOR - Multidisciplinary Oncology Cooperative Group | 65 | 2008-06-01 | 2021-09-21 |
Showing 20 of 54. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Colonic Neoplasms (6) · Leukemia (6) · Multiple Myeloma (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Rectal Neoplasms (6) · Colorectal Neoplasms (5) · Congenital Abnormalities (5) · Leukemia, Myeloid, Acute (5) · Lung Neoplasms (5) · Lymphoma, Follicular (5) · Breast Neoplasms (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (4)
City of Hope Medical Center (8) · Case Comprehensive Cancer Center (4) · Fred Hutchinson Cancer Center (3) · Mayo Clinic (3) · University of Nebraska (3) · Vanderbilt-Ingram Cancer Center (3) · AIDS Malignancy Consortium (2) · Barbara Ann Karmanos Cancer Institute (2) · French Innovative Leukemia Organisation (2) · National Cancer Institute (NCI) (2) · Roswell Park Cancer Institute (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Washington (2) · Abramson Cancer Center at Penn Medicine (1) · American College of Radiology Imaging Network (1)
United States (41) · France (4) · Canada (2) · United Kingdom (2) · Ireland (1) · South Korea (1) · Switzerland (1)
Brenda Cooper, MD (2) · Jean-Francois Rossi, MD, PhD (2) · Alan K. Burnett, MD, FRCP (1) · Amelie Lansiaux, MD, PhD (1) · Amit M. Oza, MD (1) · Angela Davies, MD (1) · Anjali Advani, MD (1) · Ann Woolfrey, MD (1) · Caroline Robert, MD (1) · Charles M. Rudin, MD, PhD (1) · Craig Okada, MD, PhD (1) · David Carbone, M.D., Ph.D. (1) · Donald W. Northfeld, MD (1) · Edith A. Perez, MD (1) · Ehsan Malek, MD (1)
PMID 18090584, PMID 21321091, PMID 23032420, PMID 23041588, PMID 25057165, PMID 25173583, PMID 25621498, PMID 28684537, PMID 28925785, PMID 29954415, PMID 35135810, PMID 42291584
P30CA033572 (5), P30CA036727 (3), P30CA015083 (2), P30CA068485 (2), U01CA121947 (2), 2008 (1), P01CA018029 (1), P30CA006973 (1), P30CA015704 (1), P30CA016086 (1), P30CA022453 (1), P30CA043703 (1), P30CA069533 (1), P30CA072720 (1), R01AI053193 (1)